The Optimisation & Developability program brings together leaders in biophysical profiling, computational design, and machine learning to build drug-ready biologics from the outset. Talks will highlight how predictive modelling and AI-driven optimization are reshaping the early engineering of antibodies, multispecifics, and conjugates, enabling multi-objective design that balances potency, biophysical behaviour, and manufacturability. A dedicated developability segment will explore next-generation workflows that integrate in silico prediction with experimental validation, embedding drug readiness into discovery and reducing the risk of late-stage attrition as biologics progress from molecule to robust clinical product.